{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T16:04:05Z","timestamp":1774454645563,"version":"3.50.1"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T00:00:00Z","timestamp":1767744000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T00:00:00Z","timestamp":1767744000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Indian Pediatr"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s13312-025-00248-6","type":"journal-article","created":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T11:16:55Z","timestamp":1767784615000},"page":"266-270","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cyclophosphamide and Topotecan in Relapsed and Refractory Pediatric Extracranial Solid Tumors: A Retrospective Analysis"],"prefix":"10.1007","volume":"63","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1957-1279","authenticated-orcid":false,"given":"Pragadeesh","family":"Thamaraiselvan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4596-2820","authenticated-orcid":false,"given":"Gargi","family":"Das","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-4036-0580","authenticated-orcid":false,"given":"Prasanth","family":"Srinivasan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2953-3188","authenticated-orcid":false,"given":"Balaji","family":"Thiruvengadam Kothandan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2585-8527","authenticated-orcid":false,"given":"Anand","family":"Raja","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7557-5816","authenticated-orcid":false,"given":"Venkatraman","family":"Radhakrishnan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,7]]},"reference":[{"key":"248_CR1","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/S1470-2045(17)30186-9","volume":"18","author":"E Steliarova-Foucher","year":"2017","unstructured":"Steliarova-Foucher E, Colombet M, Ries LAG, et al. International incidence of childhood cancer, 2001\u201310: a population-based registry study. Lancet Oncol. 2017;18:719\u201331.","journal-title":"Lancet Oncol"},{"key":"248_CR2","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1016\/S1470-2045(19)30339-0","volume":"20","author":"LM Force","year":"2019","unstructured":"Force LM, Abdollahpour I, Advani SM, et al. The global burden of childhood and adolescent cancer in 2017: an analysis of the Global Burden of Disease Study 2017. Lancet Oncol. 2019;20:1211\u201325.","journal-title":"Lancet Oncol"},{"key":"248_CR3","doi-asserted-by":"publisher","first-page":"285","DOI":"10.4103\/ijc.IJC_787_20","volume":"58","author":"V Radhakrishnan","year":"2021","unstructured":"Radhakrishnan V. Cancer in children: the tip of the iceberg. Indian J Cancer. 2021;58:285.","journal-title":"Indian J Cancer"},{"key":"248_CR4","doi-asserted-by":"publisher","DOI":"10.4103\/crst.crst_375_20","volume":"4","author":"V Radhakrishnan","year":"2021","unstructured":"Radhakrishnan V, Howard S, Lam C. Pediatric cancers in India: the forgotten disease. Cancer Res Stat Treat. 2021;4:6.","journal-title":"Cancer Res Stat Treat"},{"key":"248_CR5","doi-asserted-by":"publisher","first-page":"3463","DOI":"10.1200\/JCO.2001.19.15.3463","volume":"19","author":"RL Saylors","year":"2001","unstructured":"Saylors RL, Stine KC, Sullivan J, et al. Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: a pediatric oncology group phase II study. J Clin Oncol. 2001;19:3463\u20139.","journal-title":"J Clin Oncol"},{"key":"248_CR6","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1200\/JCO.1998.16.3.945","volume":"16","author":"RL Saylors","year":"1998","unstructured":"Saylors RL, Stewart CF, Zamboni WC, et al. Phase I study of topotecan in combination with cyclophosphamide in pediatric patients with malignant solid tumors: a pediatric oncology group study. J Clin Oncol. 1998;16:945\u201352.","journal-title":"J Clin Oncol"},{"key":"248_CR7","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1002\/1096-911X(20001101)35:5<468::AID-MPO5>3.0.CO;2-P","volume":"35","author":"BH Kushner","year":"2000","unstructured":"Kushner BH, Kramer K, Meyers PA, Wollner N, Cheung NKV. Pilot study of topotecan and high-dose cyclophosphamide for resistant pediatric solid tumors. Med Pediatr Oncol. 2000;35:468\u201374.","journal-title":"Med Pediatr Oncol"},{"key":"248_CR8","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1002\/pbc.20719","volume":"47","author":"A Hunold","year":"2006","unstructured":"Hunold A, Weddeling N, Paulussen M, Ranft A, Liebscher C, J\u00fcrgens H. Topotecan and cyclophosphamide in patients with refractory or relapsed Ewing tumors. Pediatr Blood Cancer. 2006;47:795\u2013800.","journal-title":"Pediatr Blood Cancer"},{"key":"248_CR9","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1097\/MPH.0b013e318270a343","volume":"35","author":"R Farhat","year":"2013","unstructured":"Farhat R, Raad R, Khoury NJ, et al. Cyclophosphamide and topotecan as first-line salvage therapy in patients with relapsed ewing sarcoma at a single institution. J Pediatr Hematol Oncol. 2013;35:356\u201360.","journal-title":"J Pediatr Hematol Oncol"},{"key":"248_CR10","doi-asserted-by":"publisher","first-page":"3808","DOI":"10.1200\/JCO.2009.27.5016","volume":"28","author":"WB London","year":"2010","unstructured":"London WB, Frantz CN, Campbell LA, et al. Phase II randomized comparison of topotecan plus cyclophosphamide versus topotecan alone in children with recurrent or refractory neuroblastoma: a Children\u2019s Oncology Group study. J Clin Oncol. 2010;28:3808\u201315.","journal-title":"J Clin Oncol"},{"key":"248_CR11","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1002\/pbc.24587","volume":"60","author":"K Ashraf","year":"2013","unstructured":"Ashraf K, Shaikh F, Gibson P, Baruchel S, Irwin MS. Treatment with topotecan plus cyclophosphamide in children with first relapse of neuroblastoma. Pediatr Blood Cancer. 2013;60:1636\u201341.","journal-title":"Pediatr Blood Cancer"},{"key":"248_CR12","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.30179","volume":"70","author":"S Ramanathan","year":"2023","unstructured":"Ramanathan S, Prasad M, Vora T, et al. Outcomes of relapsed\/refractory extracranial germ cell tumors treated on conventional salvage chemotherapy without stem cell rescue: experience from a tertiary cancer center. Pediatr Blood Cancer. 2023;70:e30179.","journal-title":"Pediatr Blood Cancer"},{"key":"248_CR13","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1089\/jayao.2020.0016","volume":"10","author":"K Vijayasekharan","year":"2021","unstructured":"Vijayasekharan K, Ramanathan S, Chinnaswamy G, et al. High response rates and promising outcomes of patients with relapsed ewing sarcoma, especially in adolescents and young adults treated on a novel hybrid salvage chemotherapy regimen. J Adolesc Young Adult Oncol. 2021;10:185\u201392.","journal-title":"J Adolesc Young Adult Oncol"},{"key":"248_CR14","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1001\/jamaoncol.2017.0324","volume":"3","author":"R Pramanik","year":"2017","unstructured":"Pramanik R, Agarwala S, Gupta YK, et al. Metronomic chemotherapy vs best supportive care in progressive pediatric solid malignant tumors: a randomized clinical trial. JAMA Oncol. 2017;3:1222\u20137.","journal-title":"JAMA Oncol"},{"key":"248_CR15","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1158\/2326-6066.CIR-19-0692","volume":"8","author":"DL Casey","year":"2020","unstructured":"Casey DL, Cheung NKV. Immunotherapy of pediatric solid tumors: treatments at a crossroads, with an emphasis on antibodies. Cancer Immunol Res. 2020;8:161\u20136.","journal-title":"Cancer Immunol Res"}],"container-title":["Indian Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13312-025-00248-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13312-025-00248-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13312-025-00248-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T15:38:56Z","timestamp":1774453136000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13312-025-00248-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,7]]},"references-count":15,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["248"],"URL":"https:\/\/doi.org\/10.1007\/s13312-025-00248-6","relation":{},"ISSN":["0019-6061","0974-7559"],"issn-type":[{"value":"0019-6061","type":"print"},{"value":"0974-7559","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,7]]},"assertion":[{"value":"16 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"None.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Institutional Ethics Committee, Cancer Institute (WIA), Adyar, Chennai, Tamil Nadu; Ref. No. IEC\/2025\/Jan 04 dated January 30, 2025.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}}]}}